Cultured primary peripheral blood mononuclear cells (PBMC) represent a potentially physiologic in vitro model of HIV-1 infection, but assessment of antibody-mediated HIV-1 neutralization using PBMC has been hindered by donor variability and lack of a sustainable individual PBMC source. To advance this model for HIV vaccine evaluation, intra-and inter-assay variability were assessed using monoclonal and polyclonal antibodies and PBMC targets from multiple HIV-seronegative donors. Inter-assay variability was introduced by using different PBMC for virus propagation, and more substantially, for assay targets. Neutralization titers varied by as much as 4 logs when using different individual donor PBMC as targets; variability was antibody-specific, with the greatest variation observed using an individual polyclonal plasma. Pooling of multiple PBMC donors significantly reduced median inter-assay variation to the level of intra-assay variation, suggesting a pathway forward for establishing a uniform, sustainable and standardized approach to the assessment of antibody function using a PBMC model.
Introduction
It is generally believed that elicitation of broadly cross-reactive antibodies will be important for an efficacious HIV-1 vaccine and may be critical for inducing sterilizing immunity (McMichael, 2006) . While the development of vaccine approaches to elicit antibodies has evolved considerably during the past two decades, so too have the assays to assess neutralizing antibodies (NAb) elicited by new products and by natural HIV infection (Albert et al., 1990; Darden et al., 2000; Holl et al., 2006; Mascola et al., 2005; Mascola et al., 2002; Nara and Fischinger, 1988; Petropoulos et al., 2000; Polonis et al., 2008; Robert-Guroff et al., 1986) . Accurate and precise quantitation of HIV-1 neutralization has remained a challenge facing HIV vaccine researchers, and several organizations have promoted efforts to increase neutralization assay standardization. These groups include the National Institutes of Health Division of AIDS NIH/DAIDS (D'Souza et al., 1997) , The World Health Organization Neutralization Network WHO/NeutNet (Fenyo et al., 2009; Heyndrickx et al., 2012) and the Collaboration for AIDS Vaccine Development (CAVD) funded by the Bill and Melinda Gates Foundation (Brown et al., 2012; Edmonds et al., 2010) . Different assay platforms have been applied for assessing HIV neutralization; pseudovirus-based assays utilizing CCR5-expressing cell lines were initially advanced as a standardized, reproducible and portable methods for assessing vaccine-induced NAb . The use of peripheral blood mononuclear cells (PBMC) for HIV-1 neutralization assays has long been considered to be an important platform, which may incorporate a degree of physiologic relevance (Fenyo et al., 2009; Heyndrickx et al., 2012; Mann et al., 2009; Paul et al., 2010; Polonis et al., 2009; Rusert et al., 2009) . In this in vitro system, activated PBMC (containing a mixture of cell types, including the CD4 þ T lymphocytes presumed to be a target for HIV in vivo) are used for propagation of HIV-1 isolates and as assay targets. However, this platform has been plagued by variability, technical challenges and a lack of consistent PBMC donor sources. Variation in PBMC from different donors has been shown to impact HIV-1 binding, susceptibility and replication kinetics (Cloyd and Moore, 1990; Spira and Ho, 1995; Wainberg et al., 1987; Williams and Cloyd, 1991) . Only recently has the effect of donor variation been appreciated with respect to neutralizing antibody titers (Brown et al., 2012; Edmonds et al., 2010; Moody et al., 2010; Paul et al., 2010) . Several lines of evidence have highlighted divergent results obtained when using specific neutralization assays (i.e. reporter cell line-based pseudovirus assays versus PBMC assays) and using particular antibodies (Binley et al., 2004; Brown et al., 2007; Brown et al., 2008; Choudhry et al., 2006; Fenyo et al., 2009; Heyndrickx et al., 2012; Ketas et al., 2007; Mann et al., 2009; Moody et al., 2010; Rusert et al., 2009 ). It appears that certain antibodies or inhibitors show greater potency in one assay system than the other, with both assays failing to detect different subsets of NAb. The relevance of the data generated in these different in vitro systems is still under consideration, and it remains unclear as to which functional assay(s) are predictive of in vivo outcomes. Currently, the TZM-bl pseudovirus assay, which is highly reproducible and readily established in international settings , has been a preferred assay for immunogenicity in many vaccine trials (Bakari et al., 2011; Haynes et al., 2012) . In addition, a CCR5 þ T cell line (A3/R5-7) has also recently been applied for vaccine assessment (McLinden et al., in preparation; Montefiori et al., 2012) . Until the best functional assay correlates are defined, it will be important to assess antibody responses in both the well-standardized cell line platforms, as well as in assays employing primary cells. This will be facilitated through a better understanding of the sources of variation in these assays, and by devising methods to increase reproducibility.
In the initially developed PBMC assays, uncloned primary HIV-1 isolates were used in approaches employing the reduction of HIV-1 p24 gag protein production as an endpoint. New molecular tools have recently been developed to facilitate the assessment of HIV inhibition, including infectious molecular clones (IMC) that carry a luciferase reporter gene and can be used with primary cell targets such as PBMC Edmonds et al., 2010) . These reagents have made it possible to conduct a large number of assays using multiple antibodies and PBMC targets with higher throughput. The present study was initiated through the CAVD Comprehensive Antibody-Vaccine Immune Monitoring Consortium (CA-VIMC) to characterize the influence of individual donor PBMC on assay variability, and to facilitate PBMC neutralization assay standardization. In this study, we have employed both monoclonal and polyclonal antibodies along with well-characterized reporter IMC, to assess the variation contributed by differences in donor PBMC, and to devise methods to reduce this variation. Here we demonstrate that, in addition to screening donors for particular genetic polymorphisms (Brown et al., 2012) and for HIV permissivity, pooling of different donor PBMC is a means to mitigate inter-assay variability. These studies will provide important guidance for the approaches required for standardization of HIV inhibition assays using PBMC and other relevant primary cell types.
Results
The experimental design models used to test the effect of different PBMC targets or different PBMC virus propagation sources in PBMC neutralization assays are shown in Fig. 1 . Panel A depicts the use of a virus stock (ie. Virus A) in neutralization assays where different PBMC (Targets 1, 2 or 3) are used as assay targets. Panel B illustrates the propagation of a particular virus (Virus A) using multiple PBMC to produce this same virus from different sources (donors 1, 2 or 3). This is followed by use of the different stocks (ie. Virus A/1 or A/2 or A/3) in NAb assays using a single PBMC donor or cell line (Target 1) to assess variability introduced in the results due to virus stock variation. The data that follow indicate both of these scenarios as sources of inter-assay variation, defined as the fold difference between ID50 or IC50 values generated in two assays for which only one variable, either the source of PBMC used for assay targets or for viral propagation, was altered.
We first sought to determine the extent of the variability in the PBMC neutralization assay when using IMC produced directly from 293T cells after transfection, or by passaging 293T-derived IMC through one individual PBMC donor. Additionally, these two types of stocks were tested using multiple individual PBMC targets. Fig. 2 demonstrates that use of different PBMC as targets for HIV-1 neutralization results in significant variation in neutralization titers. Twenty different donor PBMC were used as targets to assess neutralization profiles for two Renilla luciferase expressing IMC, SF162 ( Fig. 2A) and BaL (Fig. 2B) ; both subtype B IMC were produced from 293T cells (open circles) or passaged through PBMC from a single donor (closed circles). 293T-derived IMC were consistently more infectious than PBMC propagated IMC, however, no correlation between neutralization sensitivity and target infectivity was found (data not shown). The IC 50 or ID 50 values obtained by two operators were accepted and averaged if the range between operators was less than 5-fold, an arbitrarily defined The same virus stock (virus A) was tested using specific antibodies and using 3 different individual PBMC as target cells. (B) A specific virus (virus A) was passaged to produce different virus stocks derived from donor 1 (virus A/1), donor 2 (virus A/2), and donor 3 (virus A/3) and then tested against the three stocks using specific antibodies, but the same PBMC (Target 1) for target cells. maximum acceptable intra-assay variability . No significant differences were observed in neutralization profiles for the PBMC-derived versus 293T-derived IMC. However, altering the PBMC used as targets induced inter-assay variability that was neutralization reagent-specific, and occurred even when 293T-derived virus was used. As can be seen in Fig. 2 , the neutralization titers observed for the same virus/antibody pair could vary by as much as four logs and was most pronounced for an individual HIVþ polyclonal plasma (Ind.). As might be expected, the least variation was observed for sCD4-mediated inhibition.
A spectrum of sensitivity of detection was observed among the 20 PBMC targets tested when titers for each reagent were ranked and scored based on quartiles (Supplementary information Fig. 1 ). For example, when using BC177 as the assay target, 93% of the neutralizing titers were in the top two quartiles (most potent neutralizing titers), while using BC165 as assay targets, 93% of neutralizing titers were in the bottom two quartiles (least potent neutralizing titers); this difference was statistically significant (p o0.0001). Titers were also determined for all reagents using the two 293T-derived IMC in a TZMbl target cell neutralization assay (Fig. 2, red squares) . TZMbl titers fell within the data range shown for different PBMC targets with the exceptions of sCD4-mediated inhibition of both viruses and b12 mAb against the BaL IMC, for which TZMbl IC50s showed greater potency. In addition, the polyclonal Pool and individual (Ind.) plasma reagents showed lower potency against the BaL IMC on TZM-bl target cells.
A similar level of variability was observed whether the 50% or 80% endpoints were used, as shown for the 293T-derived IMC in Supplementary information Fig. 2 . The variation was not significantly higher for the IC 50 s or ID 50 s (black dots), as compared with the IC 80 s or ID 80 s (red dots). In addition, the neutralization profiles for a given clone (BaL or SF162) did not differ when the PBMCderived or the 293T-derived stocks were used. In fact, significant correlations were observed when the titers for the PBMC-derived and 293T-derived matched IMC were compared (Spearman correlations p o0.0001 for both BaL and SF162 IMC, data not shown). This is not surprising, as the same env clone was assessed in both approaches.
The inter-assay variation for each inhibitory reagent was also assessed by combining all data points for every donor cell/reagent pair performed for each 293T-derived virus and reagent tested. In Fig. 3 , these values are graphed as fold-differences for all possible paired comparisons of the values obtained using different PBMC targets, [e.g. donor PBMC BC174, BC167 and BC172 were used to generate ID50 values of 355, 1314 and 6074, respectively for HIVþB Pool plasma using SF162 IMC, the resulting paired folddifferences were 3.7 (BC174 versus BC167), 4.6 (BC167 versus BC172) and 17.1 (BC174 versus BC172)]. Intra-assay variation (between operators using the same reagents) was independent of the reagent used and averaged 2.3-fold (n ¼ 770 assays, excluding concordant negative results, indicated in Fig. 3 as "Intra"). The black bars indicate mean fold-differences and the red line indicates the 5-fold cut-off for intra-assay variation. Inter-assay variability was calculated for all accepted assays performed in the study; values determined for each reagent (using each individual PBMC donor for targets) were then compared for all possible donor pairs. The greatest fold-differences (in IC 50 or reciprocal titer) between donor pairs (plotted as "Fold Differences" on the Y-axis) were observed using the individual HIVþ plasma (a maximum of 7850-fold difference in ID 50 s), and the least variation was observed using sCD4 (11-fold maximum difference in IC 50 s). The 2G12 mAb also showed 4100-fold differences for several donor pairs, and showed a mean fold-difference 410 (Fig. 3 ).
The effect of using different PBMC donors to propagate HIV-1, as modeled in Fig. 1B , is demonstrated in Fig. 4 . Using different US-1 subtype B virus stocks, the fold-differences between the values for the same antibodies are shown. Neutralization assays were performed either using a single donor for PBMC targets, or using TZM-bl reporter cells as targets. Virus stocks derived from propagating the US-1 subtype B primary isolate in five different individual PBMC donors were used as innocula and tested against the b12, 2G12, 2F5 and 4E10 mAbs in a p24 endpoint neutralization assay (PBMC targets) or in the luciferase reporter-based TZMbl cell line. Inter-assay differences of up to 48-fold could be seen in IC 50 s when exchanging the different US-1 virus stocks and using the same PBMC as targets (Fig. 4) , but the overall variability induced by altering the virus stock was much lower than that observed when using the same stock and varying the PBMC targets (as shown in Fig. 3 ). To assess whether the variability induced by changing virus source would also be observed using a cell line target, we performed the same neutralization experiments using the reporter cell line, TZM-bl. The viral PBMC propagation source did not contribute to inter-assay variability when using the cell line as targets, as shown in Fig. 4 . The mean inter-and intra-assay fold-differences were both approximately 1.5. The inter-assay folddifferences induced by varying the virus stocks were significantly higher when a PBMC donor target was used, as compared to when the cell line target was used (po0.0001 for 2F5, 4E10 and b12; p ¼0.0012 for 2G12) (Fig. 4) .
Once we had quantified the degree of variation observed using this collection of PBMC, a well-known panel of antibodies and two well-characterized IMC, we then sought to explore methods that might reduce this variability. To normalize the neutralization profiles observed using individual targets, PBMC were pooled in efforts to create larger collections of target cells that might be more uniform over a series of experiments. We first assessed the effects of PBMC pooling on virus growth, and saw little or no change in virus titers for the two IMC (BaL and SF162) produced in either PBMC or 293T cells, and titered on each of three individual donors versus the pool of all three. As shown in Supplementary information Fig. 3 , although the variation was somewhat increased when PBMC propagated stocks were used, the titers obtained on any individual donor (black symbols) versus the pool of the three donors (red triangle) were all within 4-fold.
To assess the effects of pooling PBMC targets in neutralization assays, a subset (fourteen) of the twenty original donors (used for Fig. 2 ) were used either as individual PBMC targets, or in pools of four donors; each pool of four varied in composition. In Fig. 5 , the IC 80 s against both BaL and SF162 IMC using 2G12 (A), 4E10 (B), sCD4 (C), and the reciprocal 80% titers for the HIV þB individual plasma (D), the HIVþB pooled sera (E), and an HIV negative human serum pool (F) are displayed. IC 80 /ID 80 values were reported instead of IC 50 /ID 50 to effectively compare values for pools versus individual donors, as certain reagents showed greater potency when using pooled PBMC targets. Each reagent value is graphed for data obtained using the 14 different PBMC (Individual) and using 9-15 different pools of four PBMC (Pool). Pooling the PBMC targets appears to normalize neutralization values and reduced the ranges (or maximum fold-differences) between titers by nearly a log for the polyclonal reagents. For both polyclonal reagents and sCD4, the mean values of the individual PBMC titers were nearly identical to the mean values obtained when using pooled donor targets (as indicated by the center black lines). However, for HIV þB individual plasma and SF162 IMC, pooling donor targets statistically reduced the range and increased the median titer of measured ID 80 s (p¼ 0.008). In the case of 2G12 and 4E10, PBMC pooling resulted in a statistically greater level of neutralization measured for BaL IMC (p¼ 0.002) (Fig. 5A ). This was a reproducible finding and the mechanism for this increase in antibody activity when pooled PBMC are used is under investigation. A non-neutralizing value of 25 (Fig. 5A-C) or 40 ( Fig. 5D-F) was graphed for all titers o25 μg/ml or reciprocal titers o 40 respectively, as 25 μg/ml and 1:40 were the highest concentration or lowest dilution tested (see dashed red lines). No variability or Fig. 4 . Virus stock propagation using different PBMC donors induces variation in IC 50 s when using PBMC, but not cell line targets. Virus stocks derived from propagating the US-1 subtype B primary isolate in five different individual PBMC donors were tested against the b12, 2G12, 2F5 and 4E10 mAbs in a p24 endpoint neutralization assay (single PBMC targets) or in the luciferase reporter-based TZMbl assay. The fold differences between values obtained using all possible paired comparisons of the five virus stocks tested were combined and shown as Interassay variability. The Intra-assay variability is displayed in the fold-differences obtained between operators using the same reagents. Fig. 5 . Pooling of donor PBMC reduces the variation in neutralization observed in the PBMC assay. The IC 80 s against both BaL and SF162 293T-derived IMC are shown for 2G12, 4E10, and sCD4 in panels A, B and C, respectively. The reciprocal 80% titers for the HIV þB Individual plasma (D), the HIV þ B pool (E), and an HIV negative human serum pool (NHS, F) are also displayed for both viruses. Each reagent value is graphed for data obtained using the 14 different PBMC (Individual) and using 9-15 different pools of four PBMC (Pool).
increased background was observed for the HIV-negative serum control when using either individual or pooled PBMC (Fig. 5F ).
We next asked whether or not pooling higher numbers of donor PBMC could have an even greater impact on normalizing neutralization titers. For these experiments, 10 of the 20 original donors were tested as individual PBMC targets (1), or were used to make 5 pools of 2, 4, 6 or 8 different donors of varying composition. As shown in Fig. 6 , pooling of as few as two different PBMC donors can mitigate the variation in neutralization titers against the SF162 IMC in the PBMC assay, particularly when testing the 3 mAbs (2G12, b12, 2F5); significant reductions are indicated by an asterix (n). It also appears that pooling of increased numbers of different PBMC results in a further decrease in the fold-differences observed between values compared for donor pools, particularly for the polyclonal antibodies. When the pools consisted of 8 donors, nearly all (except one value for the HIVþB Pooled Sera) values plotted for fold-differences remained below the 5-fold level (Fig. 6, far right) , substantially reducing the individual donor variation observed in the PBMC assay to nearly that observed when using cell lines. When combing the data across reagents, pools of 4, 6 or 8 PBMC showed significantly reduced variation compared with individual PBMC (1) (p o0.0001); the pool of 2 PBMC was influenced by the higher variability observed with the HIVþB Ind plasma.
Discussion
Most HIV vaccine researchers believe that a functional antibody response will be a critical component of a successful vaccine. This view is supported by the protection from infection observed in passive transfer experiments using neutralizing mAbs in animal models (Baba et al., 2000; Hessell et al., 2010; Mascola, 2002; Mascola et al., 2000; Nishimura et al., 2003; Parren et al., 2001; Shibata et al., 1999) . Although the role of NAbs in HIV pathogenesis and protection remains to be completely defined, eliciting an antibody response capable of neutralizing primary isolates of multiple HIV subtypes continues to be a goal of laboratories that are developing and testing vaccines. It is therefore thought that in vitro neutralization or HIV inhibition studies will contribute to the selection of HIV-1 envelopes for incorporation into candidate vaccines. In the RV144 Phase III canary pox prime and protein boost vaccine trial conducted in Thailand, specific binding antibodies against envelope, including antibodies against the V2-loop of gp120, were the only demonstrated correlate of protection , highlighting the potential importance of the accurate and physiologic measurement of functional antibody activities.
In the present study, we assessed the influence of the use of different PBMC donor cells in HIV-1 inhibition assays. Varying the PBMC source for viral propagation induced some inter-assay variation when a primary isolate was utilized, and this variability due to propagation source was eliminated when using the TZM-bl cell line as a target. In a study of neutralization of pseudoviruses and primary isolates comparing both TZM-bl cells and PBMC as neutralization targets, Mann et al. (2009) reported that both the virus producer cells and target cells influence the magnitude of neutralization, with the target cell differences exerting a more dominant effect. Our findings are in agreement with this report, as we also observed that using different individual PBMC targets has the most pronounced effect on assay variability. In another study comparing neutralization activities of 11 reagents against 30 pseudotyped viruses and using PBMC versus TZM-bl cell targets, Rusert et al. found that, depending on the type of inhibitor used, neutralization potencies could be shifted to a variable extent, depending on the targets employed. They also observed that CD4 binding site activities were the least affected by the target cell environment ). The inter-assay variability induced by altering the source of PBMC targets in our study was also neutralization reagent-specific, with the greatest variability measured (over 4 logs) when an individual polyclonal plasma was tested and the lowest variability observed using soluble CD4. These findings have important implications for evaluation of vaccine sera, and should be taken into consideration when standardizing vaccine immunogenicity assays.
Numerous studies have highlighted differences that can be observed in neutralization results, depending on the assay chosen and on assay-specific parameters (such as virus dose and source, incubation times, target cells, cell densities, etc.), and depending on the antibodies employed in the assay. Studies of anti-lipid mAbs, such as phosphatidyl inositol phosphate (PIP) mAbs, have shown that targeting lipids in close proximity to the viral or host cell machinery involved in HIV-1 infection can result in neutralization of the virus. Some of these mAbs neutralized HIV-1 only in assays where PBMC were used as target cells, and not in the TZMbl cell pseudovirus assay (Brown et al., 2007; Moody et al., 2010) . One explanation for the discrepancy observed between cell line and PBMC assays was the finding that certain antibody samples may contain endotoxin, which can in turn induce monocytes present in the PBMC to produce beta-chemokines that will inhibit HIV-1 infection, confounding data interpretation (Geonnotti et al., 2010) . In addition, certain antibodies appear to bind to target cell plasma membrane constituents, which also can induce production of beta-chemokines in the PBMC assay (Matyas et al., 2010; Moody et al., 2010) . The numbers of monocytes remaining in the PBMC assay after cell stimulation would then contribute to variation in data obtained using different PBMC sources, and different cell stimulation protocols. In prior studies, we found that the CD14 þ monocytes were substantially decreased due to adherence after a 3-4 day PHA-stimulation. Thus, in our targets, variation in numbers of monocytes should have little impact on the data (Brown et al., 2012) . Furthermore, we found that CD8 T celldepletion influenced viral propagation in only about 50% of the donors tested, thus, the expense and labor associated with depleting CD8 cells did not appear to be beneficial in our standardization efforts. Additionally, our laboratory recently reported the significant effects that variation in the number of natural killer (NK) cells in PBMC targets can have on the results of PBMC neutralization assays. Especially when using polyclonal sera and bulk PBMC where NK cells are present, the HIV inhibition observed in a four-day assay appeared to extend beyond the process of neutralization of viral entry, with potential ADCC or Fig. 6 . Pooling as few as two donor PBMC targets can reduce the variation in neutralization titers against SF162 IMC; pooling of 8 donors reduced variation for all five antibodies to intra-assay levels. Ten of the 20 original donors (see Fig. 2 ) were tested as individual PBMC targets (1), or were used to make 5 different pools of 2, 4, 6 or 8 different donors (pools were of varying composition). For each of the 5 neutralizing antibodies shown, the fold-differences in IC 50 s or ID 50 s comparing all possible pairs of targets are shown. Statistically significant reductions in variability using pooled PBMC as compared to individual PBMC are marked indicated by an asterix (*).
other Fc-receptor mediated effects measured (Brown et al., 2012) . This has been observed using human vaccine sera from the HIVIS vaccine trials using DNA prime and MVA boost. In the initial trial assessed (HIVIS03), the vaccine sera were negative in the TZM-bl assay (including Tier 1 viruses), but positive in the PBMC assay (Bakari et al., 2011) . In subsequent studies, the HIV inhibitory activity was lost when the target cells were depleted of NK cells (Joachim et al., 2012 (Joachim et al., , 2013 . These findings indicate that differing numbers of NK cells in leukophoresis donors will also contribute to variability between HIV inhibition assays using PBMC target cells. In our study on the influence of NK cells in PBMC-based HIV neutralization, the numbers of CD4 þ and CD8 þ T cells in the PBMC donors did not significantly influence neutralization, while NK cell depletion did (Brown et al., 2012) . Pooling of PBMC from multiple different donors might normalize variables from pool to pool, creating target cell environments that represent a composite sampling of mixtures of multiple different types of primary effector and target cells.
We now demonstrate that pooling of previously cryopreserved PHA-stimulated PBMC targets from multiple donors can mitigate some of the inter-assay variability observed in the PBMC neutralization assay. In their studies, both Rusert and Mann utilized fresh, CD8-depleted PBMC pooled from three donors and then stimulated with PHA and/or anti-CD3 mAb (with low standard deviations observed) Rusert et al., 2009) . These data highlight the multiple differences in PBMC preparation protocols used amongst different laboratories, and also indicate the potential utility of donor cell pooling. In our study, donor PBMC pooling reduced the variability, with little change in the overall mean neutralization profiles observed for most virus/antibody pairs. Studies performed in the Hanson laboratory at the California Department of Public Health have also demonstrated an averaging effect on neutralization titers for anti-gp120 IgGs and IgAs, when pooled donor PBMC target cells were compared with individual donors (Paul et al., 2010) . Donor pooling may also provide additional benefits for HIV propagation. For example, pools of 3-4 donors have been shown to be superior to the composite individual donors for isolation and propagation of acute primary HIV-1 from plasmas collected during Fiebig stage I (Lai-Hipp et al., 2011) . Thus, the use of pools of PBMC from multiple donors may extend beyond the standard benefit of having an abundant and more sustainable source of cells for assessment of large numbers of samples from clinical protocols. While we did not preselect donors based on CD8 T cell or NK cell numbers for this study, in future studies it will be interesting to address further standardization of the assay and data normalization by preparing pools of purified CD4 T cells or CD8-depleted and NK-cell depleted donors to assess the influence of these parameters on assay variation.
The source of the virus stocks used may also contribute to variations observed in neutralization platforms. The complexity of env quasispecies in primary isolate stocks, as compared to a single env used to make pseudoviruses or IMC, might generate differences between assays. In addition, variations in the viral envelope lipid bilayer, as produced in lymphocytes versus transformed epithelial cells, or as produced in cells from different PBMC donors, can also play a role in the differences observed in HIV inhibition or neutralization (as shown for the US-1 primary isolate, Fig. 4) . Primary virus stocks grown in PBMC incorporate multiple host proteins into the virus envelope, to include ICAM-1 and HLA-DR, which have been shown to aid in infectivity, and potentially, in evasion of neutralizing antibodies (reviewed in (Cantin et al., 2005; Kolegraff et al., 2006) ). The 293T cells used to produce pseudoviruses and IMCs lack ICAM-1 and HLA-DR, which can alter neutralization sensitivity. A study of the neutralization profiles for three viral strains produced as pseudoviruses or IMCs in 293T cells, or as PBMC-derived stocks through a single passage of the IMCs in PBMC, was previously performed. While the 293T derived-IMCs were more neutralization sensitive compared with PBMCpassaged IMCs, the neutralization profiles for different envelopes appeared to be consistent (Louder et al., 2005) , similar to findings reported here.
The use of novel reporter IMCs as the virus source reduced PBMC assay workload, but not the variation related to PBMC donor differences. A major objective of the studies presented here was to identify methods to control the variables associated with PBMC donor differences to facilitate advancement of a platform for vaccine evaluation wherein primary cells can be utilized, in hopes of increasing the physiologic relevance of methods employed. However, it has not been conclusively proven that any particular neutralization assay is the best predictor of vaccine efficacy or clinical outcome. There are simply reports in the literature that describe how data obtained in particular assay platforms relate to what can be observed in vivo. For example, in a study of clinical isolates obtained from subjects passively immunized with the 2G12 neutralizing mAb, the in vivo activity of 2G12 (the emergence of 2G12 escape mutations) was the best corroborated by the data obtained using a PBMC assay. In the TZM-bl pseudovirus system, 50% of the viruses failed to reflect the emergence of 2G12 resistance after passive immunization .
In another study using samples from HIV-infected patients, a clade-specific neutralization pattern with more potent neutralization of matched-clade viruses using pooled antibodies was demonstrated using primary isolates and a PBMC neutralization assay. The matrix assessing a single representative Env-pseudotyped virus from each isolate and the same antibody pools demonstrated a completely different pattern of cross-clade neutralization, with little association between matched-clade reagents . The identification of cross-clade relationships using a system where activated primary lymphocytes are used as both target cells and as producer cells for virus stocks, seems somewhat intuitive and could be interpreted as in vivo relevant when using polyclonal antibodies from natural infection. On the other hand, in several studies, pseudovirus assays have been predictive or reflective of in vivo escape and viral evolution in natural infection (Liao et al., 2013; Montefiori et al., 2003; Richman et al., 2003) . Additionally, subtypespecific neutralization patterns have also been observed in other studies using the pseudovirus assay (Li et al., 2006; Moore et al., 2011; Oballah et al., 2011; Seaman et al., 2010) .
Although there are identifiable disparities between neutralization profiles obtained using different assay platforms, it is unclear what the relative contribution of any specific assay will be toward elucidating the correlates of in vivo protection, and toward selecting the best candidate vaccine(s). Progress in HIV vaccine development may be accelerated if vaccine-induced and newly developed antibodies are assessed both in the rapid and reproducible pseudovirus platform, and in primary cell-based assays, until a validated correlate of antibody-mediated protection has been identified. A greater understanding of the impact of variation in human PBMC on the outcomes of functional antibody assays, particularly as applied in international settings where the cells will come from subjects with very different genetic backgrounds, will facilitate the measurement of incremental improvements in the antibody responses to HIV envelope immunogens. The evaluation and advancement of novel vaccine candidates will be facilitated by an approach that provides a comprehensive assessment of virus-antibody-host cell interactions.
Materials and methods

PBMC collection and culture
PBMC were collected by leukophoresis from healthy donors under an IRB-approved protocol. PBMC were isolated by Ficoll-Hypaque density gradient centrifugation and cryopreserved. Three days prior to the assay, PBMC were thawed, stimulated with 1 mg/ml phytohemagglutinin (PHA) (Sigma, St. Louis MO) and 20% IL-2 (Roche, Indianapolis, IN) and were cultured as previously described (Ping et al., 2013) . PBMC included in this study were selected at random and were not pre-screened for NK cells or any other population; however, PBMC containing the CCR5-Δ32 mutation were excluded. Although fresh cells may be optimal for HIV-1 replication, cryopreserved cells were used for all studies described in this manuscript in order to have a sustainable source of PBMC available for repeated use and for preparation of numerous different pooled or individual donor PBMC as assay target cells.
Viruses and antibodies
Primary isolates or infectious molecular clones (IMC) were propagated using frozen PBMC from specific individual donors demonstrated to yield viral stocks containing 410 ng/ml of p24 within four days post-infection, or were 293T cell-derived. The SF162 and BaL IMC containing the Renilla luciferase gene (LucR-IMC) were used; neutralization profiles were assessed using these stocks and different target cells. Cell line targets were used to further assess the influence of virus source, and reporter IMC tested assay design and endpoint variation. The US-1 viral isolate was propagated in peripheral blood mononuclear cells (PBMC), as previously described (Brown et al., 2005) . The range in neutralization potency using pooled versus individual constituent PBMC was assessed using sCD4 (Progenics Pharmaceuticals, Tarrytown, NY), the monoclonal antibodies (mAbs) 2G12, 2F5, 4E10, and IgG1 b12 (Polymun Scientific Immunobiologhishe, NuBdorfer Lande 11, Austria) and an individual plasma (HIV þB Ind.) or pooled polyclonal sera (HIVþ B Pool) from HIVþ subjects from the U.S. who were enrolled (with informed consent) in two different IRB approved protocols. was added to cells. Plates were then subjected to two freeze/thaw cycles. Afterward, 100 μl of reconstituted Luciferase Assay Substrate (Promega Corp., Madison, WI) was added to each well for measurements of luminescence using a Victor 2 luminometer (Perkin-Elmer Life Sciences, Shelton, CT). The wells producing relative luminescence units (RLU) 42.5 Â background were scored as positive (Li et al., 2005) and the TCID 50 was calculated by the Spearman-Karber method.
IMC stock preparation and titration
Cell line-based (TZM-bl cell) neutralization assay
Equal volumes of virus, prepared at a dilution that, in pretitrations, yielded 200,000 RLU at 48 h post-infection were incubated in triplicate with test sample, in six serial 4-fold dilutions, in 96-well culture plates with final volume of 50 μl/well at 37 1C for 1 h. A 50 μl aliquot containing 1 Â 10 4 TZM-bl cells and 60 μg/ml DEAE-dextran was added to each well for a total volume of 100 μl.
Each plate included wells with cells and virus (virus control) or cells alone (background control). After 48 h, cells were lysed, luminescence was measured as above and the 50% inhibitory dose (ID 50 ) was defined as the dilution that resulted in a 50% reduction in RLU compared to virus control wells after subtraction of background RLU.
PBMC neutralization assay
The PBMC neutralization assay endpoints were p24 production or Renilla luciferase expression. For the p24 endpoint neutralization assays, viral isolates were prepared at a dilution that, in pretitrations, yielded Z10 ng/ml p24 at 4-6 days post-infection.
Virus stocks were combined with an equal volume (25 μl) of either the test reagent or IL-2 medium [RPMI 1640 (Quality Biologics, Gaithersburg, MD) with 100 U/ml penicillin 100 mg/ ml-streptomycin (Quality Biologics, Gaithersburg, MD), 2 mM L-glutamine (Quality Biologics, Gaithersburg, MD), and 15% fetal calf serum (FCS) (Gemini Bioproducts, Woodland, CA), and containing 20 U/ml recombinant interleukin-2 (IL-2) (Roche, Indianapolis, IN)]. Samples were prepared in triplicate and incubated for 30 min at 37 1C in 96-well deep-well plates. PHA-stimulated PBMC were then added at 1.5 Â 10 5 cells per well. All PBMC were PHAstimulated individually for 3-4 days before pooling equal numbers of cells from each donor. Plates were incubated overnight, then washed twice with 400 μl of wash medium (same as IL-2 medium, but with 2% FCS instead of 15% FCS and without IL-2), then washed once with IL-2 medium, then resuspended in 200 μl of IL-2 medium and transferred to round-bottom 96-well plates. On days 4 and 6, 100 μl of culture fluid was harvested and assayed for p24
(measured by p24 antigen capture; Beckman-Coulter, Miami, FL). For the PBMC assays where LucR-IMC were used, the virus and antibodies were incubated as above, except that a dilution of IMC was employed that had yielded at least 10,000 RLU for Renilla luciferase activity in pre-titrations. Mean titers are reported from the quadratic projections of the IC 50 from 2-5 assays for each virus and neutralization reagent pair. For both methods, assays were performed by at least two different technicians; IC 50 or ID 50 values were accepted and averaged if the range was less than 5-fold, defining the intra-assay variability.
Statistical analysis
When comparing the data for inter-and intra-assay differences, the non-parametric Wilcoxon matched-pairs signed rank test was utilized to examine overall significance, and to determine which groups of data showed significant differences from the intra-assay variation observed. Data were analyzed with Prizm 4.0b (GraphPad Software, Inc., San Diego, CA). This work was supported by a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD) (U.S. Army Medical Research and Material Command), working together with the Division of AIDS, National Institute for Allergy and Infectious Diseases National Institutes of Health. The views expressed here are the private opinions of the authors and are not to be considered as official or reflecting the views of the U.S. Army, the U.S. Department of Defense, or the U.S. Government. Use of trade names is for identification only and does not imply endorsement by the U.S. government.
